An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel rejected emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for expanded access to controversial peptides, calling for loosened oversight. The vote reflects a broader shift in how policymakers view custom-mixed peptide therapies, which have drawn increasing interest from consumers seeking alternatives to standard drugs. Researchers say peptide treatments could reshape approaches to resistant infections, though concerns about safety persist. The committee's endorsement of four peptides paves the way for more expanded prescribing, even as watchdogs warn of limited evidence. Market watchers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on certain peptide candidates.